Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 5
2021 12
2022 8
2023 8
2024 11
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis.
Oh J, Arnold DL, Cree BAC, Ionete C, Kim HJ, Sormani MP, Syed S, Chen Y, Maxwell CR, Benoit P, Turner TJ, Wallstroem E, Wiendl H; Tolebrutinib Phase 3 GEMINI 1 and 2 Trial Group. Oh J, et al. N Engl J Med. 2025 May 15;392(19):1893-1904. doi: 10.1056/NEJMoa2415985. Epub 2025 Apr 8. N Engl J Med. 2025. PMID: 40202623 Clinical Trial.
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators. Montalban X, et al. Lancet Neurol. 2024 Nov;23(11):1119-1132. doi: 10.1016/S1474-4422(24)00328-4. Epub 2024 Sep 19. Lancet Neurol. 2024. PMID: 39307151 Clinical Trial.
Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
Habib AA, Zhao C, Aban I, França MC Jr, José JG, Zu Hörste GM, Klimiec-Moskal E, Pulley MT, Tavolini D, Krumova P, Lennon-Chrimes S, Smith J, Thanei GA, Blondeau K, Vodopivec I, Wolfe GI, Murai H. Habib AA, et al. Among authors: tavolini d. Lancet Neurol. 2025 Feb;24(2):117-127. doi: 10.1016/S1474-4422(24)00514-3. Lancet Neurol. 2025. PMID: 39862880 Free article. Clinical Trial.
Traditional first-line treatment failure rates in neuromyelitis optica spectrum disorder patients included in the Argentinean registry (RelevarEM).
Carnero Contentti E, Lopez PA, Patrucco L, Cristiano E, Miguez J, Silva B, Liwacki S, Tkachuk V, Balbuena ME, Vrech C, Deri N, Correale J, Marrodan M, Ysrraelit MC, Fiol M, Leguizamon F, Luetic G, Tavolini D, Mainella C, Zanga G, Burgos M, Hryb J, Barboza A, Lazaro L, Alonso R, Fernández Liguori N, Nadur D, Martinez A, Steinberg J, Carrá A, Alonso Serena M, Rojas JI. Carnero Contentti E, et al. Among authors: tavolini d. Mult Scler Relat Disord. 2024 Sep;89:105771. doi: 10.1016/j.msard.2024.105771. Epub 2024 Jul 20. Mult Scler Relat Disord. 2024. PMID: 39033591
Consensus recommendations for family planning and pregnancy in multiple sclerosis in argentina.
Liguori NF, Alonso R, Pinheiro AA, Balbuena ME, Barboza A, Bestoso S, Burgos M, Cáceres F, Carnero Contentti E, Carrá A, Cristiano E, Curbelo MC, Deri N, Fiol M, Gaitán MI, Garcea O, Halfon M, Hryb J, Jacobo M, José G, Knorre E, López P, Luetic G, Mainella C, Martínez A, Miguez J, Nofal P, Pagani Cassará F, Marcilla MP, Piedrabuena R, Pita C, Quarracino C, Rojas JI, Silva B, Sinay V, Steinberg J, Tarulla A, Tavolini D, Tkachuk V, Tizio S, Villa A, Vrech C, Ysrraelit C, Patrucco L. Liguori NF, et al. Among authors: tavolini d. Mult Scler Relat Disord. 2020 Aug;43:102147. doi: 10.1016/j.msard.2020.102147. Epub 2020 May 4. Mult Scler Relat Disord. 2020. PMID: 32442883 Review.
[Argentinean consensus guidelines on the identification and clinical care of secondary progressive multiple sclerosis].
Cristiano E, Patrucco L, Ysrraelit MC, Alonso R, Balbuena ME, Ballario C, Barboza AG, Bestoso S, Burgos M, Cáceres FJ, Carrá A, Carnero-Contentti E, Deri N, Fernández-Liguori N, Garcea O, Hryb JP, Jacobo M, Kohler E, Luetic GG, Mainella C, Menichini ML, Míguez J, Nofal PG, Piedrabuena R, Rugilo C, Saladino ML, Silva BA, Silva E, Sinay V, Tavolini D, Tkachuk VA, Villa A, Vrech C, Rojas JI. Cristiano E, et al. Among authors: tavolini d. Rev Neurol. 2021 Jan 1;72(1):23-32. doi: 10.33588/rn.7201.2020379. Rev Neurol. 2021. PMID: 33378076 Free article. Spanish.
The Argentinean multiple sclerosis registry (RelevarEM): Methodological aspects and directions.
Rojas JI, Carrá A, Correale J, Cristiano E, Fernández Liguori N, Alonso R, Alvez Pinheiro A, Balbuena ME, Barboza AG, Bestoso S, Blaya PA, Burgos M, Cabrera LM, Caride A, Carnero Contentti E, Cohen L, Curbelo C, Deri N, Divi P, Fiol M, Fracaro ME, Gaitán MI, Hryb J, Jacobo M, Knorre E, Leguizamon F, Giunta D, Alonso Serena M, Doldan ML, De Lio GF, Liwacki SDV, Lopez PA, Luetic G, Mainella C, Manzi R, Marrodan M, Martinez AD, Miguez J, Negrotto L, Nofal P, Parada Marcilla M, Pettinicchi JP, Silva BA, Silva E, Silveira F, Steinberg JD, Tavolini D, Tizio S, Tkachuk V, Vazquez G, Volman G, Vrech C, Ysrraelit MC, Zanga G, Garcea O, Patrucco L. Rojas JI, et al. Among authors: tavolini d. Mult Scler Relat Disord. 2019 Jul;32:133-137. doi: 10.1016/j.msard.2019.05.004. Epub 2019 May 15. Mult Scler Relat Disord. 2019. PMID: 31128521
Use of cannabis in patients with multiple sclerosis from Argentina.
Carnero Contentti E, López PA, Criniti J, Pettinicchi JP, Tavolini D, Mainella C, Tizio S, Tkachuk V, Silva B, Caride A, Rojas JI, Alonso R. Carnero Contentti E, et al. Among authors: tavolini d. Mult Scler Relat Disord. 2021 Jun;51:102932. doi: 10.1016/j.msard.2021.102932. Epub 2021 Apr 6. Mult Scler Relat Disord. 2021. PMID: 33848817
41 results